Pediatric Preclinical Testing Program (PPTP)
World-Renowned Biopathology Center
At any given time there are a large number of clinical trials taking place at Nationwide Children’s that offer state-of-the-art therapies and additional treatment options to your child.
The Center for Childhood Cancer and Blood Disease's mission is to expand the understanding of the pathogenesis of childhood cancer and to improve strategies for diagnosis and treatment.
Areas of Focus
Biology and therapy of rhabdomyosarcoma and other childhood tumors
Chemotherapy of childhood solid tumors
Regulation of alternative pre-mRNA splicing
Regulation and function of tumor suppressor genes
Oncolytic viral therapy in pediatric brain tumors
Affiliations and Collaborations
Celebrex, a drug currently marketed for its anti-inflammatory properties, may have anti-tumor and cancer prevention effects, particularly because it blocks STAT3 signaling, suggests new research.
Fast Tracking Children’s’ Cancer Drugs
Animal Models of Childhood Cancer Help Prioritize Adult Drugs for Children
Virotherapy May Help Treat Childhood Brain Tumors
How Do You Talk About Cancer?
How do you tell a seven-year-old she has cancer? How do you tell the same to a 17-year-old? Answers aren’t entirely clear.
Research from Nationwide Children’s is helping to clarify how the most severe form of liver cancer develops and also has identified a potential new compound for boosting the effectiveness of its current treatments.
Interleukin-6 (IL-6) is a molecule originally characterized as important in immune and inflammatory responses to protect cells under very toxic conditions. A growing body of evidence has demonstrated that overproduction of IL-6 contributes to various human diseases including autoimmune disease, chronic inflammatory disease and many types of human cancer such as liver cancer.
Read more :: Blocking Signaling Pathway to Kill Liver Cancer
Treating children with growth factors as late as five days after they receive a bone marrow or blood stem cell transplant may result in substantial cost savings and still be as clinically beneficial as treating patients one day after transplantation. These findings are from a Nationwide Children’s Hospital study appearing in Pediatric Blood & Cancer, the first study to examine whether delayed administration in pediatrics affects engraftment time.
The use of modified measles virus may represent a new treatment for a childhood brain tumor known as medulloblastoma, according to a new study appearing in Neuro-Oncology. Medulloblastoma is the most common malignant central nervous system tumor of childhood, accounting for about 20 percent of pediatric brain tumors.
A study appearing in the Journal of Pediatric Hematology/Oncology suggests that stem cell transplantation may provide severe sickle cell patients with the greatest quality of life, but more data is needed before a “gold standard” treatment can be identified.
Rapamycin, an immunosuppressant drug commonly used to prevent rejection in organ transplantation, has shown potential to inhibit tumor growth in many childhood cancers during in vitro and in vivo laboratory studies.